10x Genomics (TXG) Equity Ratio (2018 - 2026)

10x Genomics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.8 for Q1 2026.

• In Q1 2026, Equity Ratio rose 2.45% year-over-year to 0.8; the TTM figure through Mar 2026 stood at 0.8 (up 2.45% YoY), while the FY2025 annual figure was 0.76, down 1.08% from the prior year.
• Equity Ratio came in at 0.8 for Q1 2026 at 10x Genomics, up from 0.76 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.8 in Q1 2022 to a low of 0.76 in Q3 2025.
• A 5-year average of 0.78 and a median of 0.78 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio retreated 3.6% in 2022 and rose 2.47% in 2023, its largest moves.
• 10x Genomics' Equity Ratio stood at 0.78 in 2022, then declined by 1.95% to 0.77 in 2023, then rose by 0.68% to 0.77 in 2024, then retreated by 1.08% to 0.76 in 2025, then gained by 4.84% to 0.8 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.8, 0.76, and 0.76 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison